ProtaBody specializes in advanced protein engineering and design services for biotechnology applications. The company utilizes proprietary technology to develop novel protein structures with enhanced functionality. This capability supports clients in accelerating their research and development pipelines for therapeutic and diagnostic products.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody design and optimization methods are often slow, expensive, and limited in their ability to explore the vast sequence space of potential antibody candidates. Existing AI and machine learning platforms may not fully optimize critical protein properties, hindering the development of effective antibody-based therapeutics and diagnostics.
Solution
ProtaBody offers an antibody engineering platform that combines computational protein design with proprietary, in-house trained AI to optimize antibody properties at an accelerated pace and scale. The platform enables the design and engineering of antibodies with enhanced affinity, specificity, stability, and developability. By augmenting classic computational protein design with advanced AI algorithms, ProtaBody facilitates the creation of novel antibody therapeutics, diagnostics, and biomanufacturing tools with improved performance characteristics.
Target Audience
The primary customers are pharmaceutical and biotechnology companies, as well as research institutions, involved in drug discovery, diagnostics development, and biomanufacturing.
Features
- AI-driven antibody design and optimization platform
- Computational protein design augmented with in-house trained AI
- Optimization of antibody affinity, specificity, and stability
- Accelerated antibody engineering process
- Scalable platform for high-throughput antibody generation